Ann: Paradigm and Bene Execute New Collaboration Agreement, page-23

I completely agree with you on this. Whilst the agreement allows new formulations to be created and tested against new (and existing) indications, with the costs shared between PAR and bene, today's interview suggests the new indications PAR wants the focus on includes ARDs and CHF.

I'd be very nervous as an investor if they start running clinical trials for CHF and ARDs prior to product registration for OA. On the contrary, I would be a very happy investor if they wanted to focus on improving joint pain and function for various other indications since the threshold for accelerated approval will be much lower should zilosul first be approved by the FDA for OA.